AKT1 and Hyperglycemia: According to data reported from the SOLAR-1 trial, the most frequent AE related to alpelisib is hyperglycemia (65%), explained by the involvement of the PI3K/AKT pathway in glucose metabolism: AKT favors the expression of glucose transporters (GLUT4) in muscle and fat cells, while blocking liver gluconeogenesis.